Sivik Global Healthcare LLC Invests $3.29 Million in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Sivik Global Healthcare LLC purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the medical research company's stock, valued at approximately $3,285,000. Bio-Rad Laboratories makes up approximately 1.7% of Sivik Global Healthcare LLC's holdings, making the stock its 26th biggest holding.

A number of other large investors also recently bought and sold shares of the company. UMB Bank n.a. increased its holdings in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock valued at $26,000 after purchasing an additional 45 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Bio-Rad Laboratories during the third quarter worth approximately $32,000. Point72 Hong Kong Ltd purchased a new position in shares of Bio-Rad Laboratories during the 3rd quarter valued at $55,000. Quarry LP purchased a new stake in shares of Bio-Rad Laboratories during the 2nd quarter worth about $59,000. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its position in Bio-Rad Laboratories by 281.7% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 271 shares of the medical research company's stock worth $91,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Finally, Citigroup upped their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $394.20.

Bio-Rad Laboratories Stock Up 0.8 %

Shares of BIO stock traded up $2.93 on Friday, hitting $361.79. 162,710 shares of the stock were exchanged, compared to its average volume of 155,176. The business has a 50-day moving average of $340.27 and a 200 day moving average of $335.04. Bio-Rad Laboratories, Inc. has a fifty-two week low of $262.12 and a fifty-two week high of $387.99. The firm has a market capitalization of $10.13 billion, a P/E ratio of -13.24 and a beta of 0.90. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. During the same period last year, the company earned $2.33 earnings per share. The firm's revenue was up 2.8% compared to the same quarter last year. Equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.33 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.